Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - AMEXDRUG CORPFinancial_Report.xls
EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES- OXLEY ACT OF 2002 - AMEXDRUG CORPamexdrug10kexh322.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES- OXLEY ACT OF 2002 - AMEXDRUG CORPamexdrug10kexh312.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES- OXLEY ACT OF 2002 - AMEXDRUG CORPamexdrug10kexh311.htm
EX-10.13 - FIRST AMENDMENT TO LEASE EXTENDING LEASE TERM (UNITS I&J) DATED JANUARY 18, 2012 - AMEXDRUG CORPamexdrug10kexh1013.htm
10-K - AMEXDRUG CORPORATION 10K 2011-12-31 - AMEXDRUG CORPamexdrug10k20111231.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES- OXLEY ACT OF 2002 - AMEXDRUG CORPamexdrug10kexh321.htm


Exhibit 10.14
 
CHANGE IN TERMS AGREEMENT
 

Principal
$700,000.00
Loan Date
12-21-2011
Maturity
06-09-2012
Loan No.
930610000
Call/Coll
Account
Officer
RK
Initials
/s/

References in the boxes above are for Lender’s Use only and do not limit the applicability of this document to any particular loan or item.
Any Item above containing “***” has been omitted due to text length limitations.

Borrower:
Amexdrug Corporation, Dermagen, Inc.;
Lender: National Bank of California
 
Biorx Pharmaceuticals, Inc.; Royal
 
Corporate Banking Department
 
Health Care, Inc.; and Allied Med Inc.
 
12121 Wilshire Boulevard
 
7251 Condor Street
 
14th Floor
 
Commerce, CA 90040
 
Brentwood, CA 90025

 


Principal Amount:  $700,000.00
 
Date of Agreement:  December 12, 2011

DESCRIPTION OF EXISTING INDEBTEDNESS:   The Promissory Note dated June 23, 2008 in the principal amount of $150,000.00 and Business Loan Agreement (Asset Based) dated June 9, 2011 and subsequent Change in Terms Agreements dated March 3, 2009, June 9, 2009, June 9, 2010 and June 9, 2011, with an outstanding principal balance of $81,806.94 as of December 12, 2011.

DESCRIPTION OF CHANGE IN TERMS:  The Principal Amount of the Note is hereby increased from $500,000.00 to $700,000.00.

The “AFFIRMATIVE COVENANTS” section of the Business Loan Agreement (Asset Based) is hereby deleted in its entirety and the following is inserted in its place:

Tangible Net Worth Requirements.  Other Net Worth requirements are as follows:  Borrower shall maintain a minimum Net Worth of $250,000.00 as of each Fiscal Year End.  Borrower shall maintain profitability at each Fiscal Year End.

The “DEFINITIONS” section of the Business Loan Agreement (Asset Based) is hereby amended as follows:

Borrowing Base.  The words “Borrowing Base” mean, as determined by Lender from time to time, the lesser of (1) $700,000.00 or (2) 80.000% of the aggregate amount of Eligible Accounts.

Unless otherwise agreed or required by applicable law, payments will be applied first to any accrued unpaid interest; then to principal; then to any late charges; then to any escrow or reserve account payments as required under any mortgage, deed of trust, or other security instrument or security agreement securing this Note; and then to any unpaid collection costs.  Borrower will pay Lender at Lender’s address shown above or at such other place as Lender may designate in writing.

CONTINUING VALIDITY.  Except as expressly changed by this Agreement, the terms of the original obligation or obligations, including all agreements evidenced or securing the obligation(s), remain unchanged and in full force and effect.  Consent by Lender to this Agreement does not waive Lender’s right to strict performance of the obligation(s) as changed, nor obligate Lender to make any future change in terms.  Nothing in this Agreement will constitute a satisfaction of the obligation(s).  It is the intention of Lender to retain as liable parties all makers or endorsers including accommodation makers, will not be released by virtue of this Agreement.  If any person who signed the original obligation does not sign this Agreement below, then all persons signing below acknowledged that this Agreement is given conditionally, based on the representation to Lender that the non-signing party consents to the changes and provisions of this Agreement or otherwise will not be released by it.  This waiver applies not only to any initial extension, modification or release, but also to all such subsequent actions.

PRIOR TO SIGNING THIS AGREEMENT, BORROWERS READ AND UNDERSTAND ALL PROVISIONS OF THIS AGREEMENT.  BORROWERS AGREE TO THE TERMS OF THE AGREEMENT.

AMEXDRUG CORPORATION

By:__/s/ Jack N. Amin                                           
      Jack N. Amin, President/ Secretary of Amexdrug Corporation

DERMAGEN, INC.

By:__/s/ Jack N. Amin                                           
      Jack N. Amin, President/ Secretary of Dermagen, Inc.

BIORX PHARMACEUTICALS, INC.

By:__/s/ Jack N. Amin                                           
      Jack N. Amin, President/ Secretary of  Biorx Pharmaceuticals, Inc.

ROYAL HEALTH CARE, INC.

By:__/s/ Jack N. Amin                                           
      Jack N. Amin, President/ Secretary of Royal Health Care, Inc.

ALLIED MED INC.

By:__/s/ Jack N. Amin                                          
      Jack N. Amin, President/ Secretary of Allied Med Inc.

See next page for additional signers

 
 

 

CHANGE IN TERMS AGREEMENT
(Continued)
 
Loan No. 930610000
Page 2

 
PRIOR TO SIGNING THIS AGREEMENT, GUARANTORS READ AND UNDERSTAND ALL PROVISIONS OF THIS AGREEMENT.  GUARANTORS AGREE TO THE TERMS OF THE AGREEMENT.

GUARANTORS:

x__/s/ Jack N. Amin                                         
  Jack N. Amin

x__/s/ Nora Y Amin                                           
  Nora Y Amin
 

LASER PRO LENDING VER. 5.58.20.001 Copr. Harland Financial Solutions, Inc. 1997, 2011.  All rights reserved.

1096.Amexdrug Change in Terms Agreement